INTRODUCTION
Cystinuria is an autosomal recessive disorder characterized by the abnormal urinary excretion of cysteine and the dibasic amino acids in the renal tubule and epithelial cells of small intestine. [1] Two genes including SLC3A1 and SLC7A9 are associated with cystinuria and two different types of cystinuria have been known according to genetic defects. Type I of cystinuria is caused by mutations in SLC3A1, an amino acid transporter gene located on chromosome 2 (2p16. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , and consists of 10 exons ranging in span from 120 to 461 bp which encodes the b 0,+ transporter-related protein (rBAT). This protein creates the heavy chain of the renal cystine transport system (rBAT/b 0,+ AT). Due to its biological functions, 
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RESULTS
According to direct sequencing of exons 1, 3, and 8 of SLC3A1 gene, we found five patients (C4, C6, C10, C21, C23, and C25) who were heterozygote for the polymorphism G38G in exon 1 [ Figure 1a ]. G38G (c. 114A>C) makes a synonymous variant of GGA (glycine). The amino acid variant M467K detected in exon 8 in one patient (C18). This mutation also was heterozygote. M467K is a missense mutation that changes methionine (ATG) to lysine (AAG) at position 179 T/A. The methionine at codon 467 of rBAT sequences was completely conserved in all species. This mutation leads to reduction in transport activity of cystine and dibasic amino acids. M467K has been described as a pathogenic mutation [ Figure 1b ]. Two intronic variants in intron three including c. 610+147C>T and c. 610+169C>G were also identified in one patient (C20) [ Figure 1c and d].
DISCUSSION
A new heterozygote mutation in exon 1 was found in seven patients. This novel variant is located in exon 1 before initiation codon in 5' untranslated region (5'UTR) that changes G to A (c.-29A>G). Mutations in the 5'UTR cause increase or decrease of translation efficiency that recently described as a novel molecular mechanism of disease. Changes in the consensus sequence for the translation initiation may intensify context-dependent leaky scanning of ribosomes and/or initiation from a downstream AUG codon. [7] One previously identified polymorphism in codon 38 (114C-A) was also identified. G38G is synonymous variant (GGA change to GGC) because no amino acid change occurs. It only changes one codon of amino acid glycine (GGA) to another codon of glycine (GGC) at position 114 of exon 1 (c. 114A>C). In addition, the frequency of GGC codon in African, American, East Asian, European, and South Asian populations is 80%, 67%, 38%, 77%, and 86%, respectively. In our study, two known mutations (c. 610+147C>T, c. 610+169C>G) were found in intronic regions of the SLC3A1 gene (intron 3) [ Table 2 ]. Prevalence of c. 610+147C>T intronic mutation is 3%, 1%, 2%, and 1% in African, American, South Asian, and European people, respectively. [8] [9] [10] [11] [12] [13] Intronic mutation c. 610+169C>G was found in 3%, 1%, 1% 2% of African, American, European, and South Asian people, respectively (http://www.ensemble.org). All patients in our study had percutaneous nephrolithotomy. In our research, we found that1of the 25 (4%) patients had M467K mutation in exon 8. In addition, six of patients (24%) showed G38G polymorphism in exon 1 and 7 out of 25 (28%) had a new mutation in 5'UTR (c.-29A>G) in the SLC3A1 gene. Both intronic mutations (c. 610+147C>T, c. 610+169C>G) found in 1 out of 25 patients.
CONCLUSION
In conclusion, our results confirm that cystinuria is a heterogeneous disorder at the molecular level. This study contributes to the understanding of the distribution and frequency of mutations causing cystinuria in the Iranian population.
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